Wednesday, August 10, 2022
HomeCanadian NewsIMV Inc. to Announce Second Quarter 2022 Outcomes and Host a Convention...

IMV Inc. to Announce Second Quarter 2022 Outcomes and Host a Convention Name and Webcast on August 11, 2022


Article content material

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. — IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Firm”), a clinical-stage firm growing a portfolio of immune-educating therapies based mostly on its novel DPX platform to deal with stable and hematologic cancers, in the present day introduced that it’ll maintain a convention name and webcast on Thursday, August 11, 2022, at 8:00 a.m. ET to debate the corporate’s 2022 second quarter monetary and operational outcomes.

Monetary analysts are invited to hitch the convention name by registering at this hyperlink prior the decision to obtain their particular person dial-in info.

Article content material

Different events will be capable of entry the dwell audio webcast by registering on IMV web site: https://ir.imv-inc.com/events-and-presentations. The webcast shall be recorded and can then be accessible on the IMV web site for 30 days following the decision.

About IMV

IMV Inc. is a clinical-stage immuno-oncology firm advancing a portfolio of therapies based mostly on the Firm’s immune-educating platform, DPX®. By means of a differentiated mechanism of motion, the DPX platform delivers instruction to the immune system to generate a selected, strong, and chronic immune response. IMV’s lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides from survivin, a well-recognized most cancers antigen generally overexpressed in superior cancers. MVP-S additionally delivers an innate immune activator and a common CD4 T cell helper peptide. These components foster maturation of antigen presenting cells in addition to strong activation of CD8 T cell effector and reminiscence operate. MVP-S remedy has been properly tolerated and has demonstrated outlined scientific profit in a number of most cancers indications in addition to the activation of a focused and sustained, survivin-specific anti-tumor immune response. MVP-S is at the moment being evaluated in scientific trials for hematologic and stable cancers, together with Diffuse Giant B Cell Lymphoma (DLBCL) in addition to ovarian, bladder and breast cancers. IMV can also be growing a second immunotherapy leveraging the DPX immune supply platform, DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for each the survivin and MAGE-A9 most cancers proteins to elicit immune responses to those two distinct most cancers antigens concurrently. A Section 1 scientific trial in bladder most cancers, utilizing MVP-S or DPX-SurMAGE, was initiated in early 2022. For extra info, go to www.imv-inc.com and join with us on Twitter and LinkedIn.

IMV Ahead-Trying Statements

This press launch comprises forward-looking info below relevant securities regulation. All info that addresses actions or developments that we anticipate to happen sooner or later is forward-looking info. Ahead-looking statements use such phrase as “will”, “might”, “potential”, “imagine”, “anticipate”, “proceed”, “anticipate” and different comparable terminology. Ahead-looking statements are based mostly on the estimates and opinions of administration on the date the statements are made. Within the press launch, such forward-looking statements embody, however are usually not restricted to, statements concerning the potential impression of the VITALIZE examine and the anticipated date knowledge from such examine is obtainable, the Firm’s means to advance its growth technique, in addition to the prospects, for its lead immunotherapy and its different pipeline of immunotherapy candidates. Nonetheless, they shouldn’t be thought to be a illustration that any of the plans shall be achieved. Precise outcomes might differ materially from these set forth on this press launch on account of dangers affecting the Firm, together with entry to capital, the profitable design and completion of scientific trials and the well timed receipt of all regulatory approvals to start, after which proceed, scientific research and trials and the receipt of all regulatory approvals to commercialize its merchandise. IMV Inc. assumes no accountability to replace forward-looking statements on this press launch besides as required by regulation. These forward-looking statements contain identified and unknown dangers and uncertainties, and people dangers and uncertainties embody, however are usually not restricted to, these associated to the Firm’s anticipated timeline related to its money runway; the Firm’s priorities with MVP-S and its DPX supply platform, the potential for its supply platform and the anticipated timing of enrollment and outcomes for its scientific trial packages and research as others dangers detailed once in a while in our ongoing quarterly filings and annual info type. Buyers are cautioned to not depend on these forward-looking statements and are inspired to learn IMV’s steady disclosure paperwork, together with its present annual info type, in addition to its audited annual consolidated monetary statements which can be found on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar.

View supply model on businesswire.com: https://www.businesswire.com/information/house/20220804005368/en/

logo

Contacts

Investor Relations

Irina Koffler, Managing Director, LifeSci Advisors
O: (646) 970-4681
M: (917) 734-7387
E: ikoffler@lifesciadvisors.com

Media

Delphine Davan, Senior Director, Communications and Investor Relations, IMV Inc.
O: (902) 492.1819 ext: 1049
E: ddavan@imv-inc.com

Madeline Joanis, Senior Account Government, LifeSci Communications
M: (603) 479 5267
E: mjoanis@lifescicomms.com

#distro



RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments